UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (date of earliest event reported): May 9, 2023
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation or organization) | (Commission File Number) | (I.R.S. Employer Identification No.) | ||||||||||||||||||
(Address of Principal Executive Offices) | (Zip Code) | |||||||||||||||||||
(800 ) 298-6470
Registrant's telephone number, including area code
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐
Item 2.02 Results of Operations and Financial Condition.
On May 9, 2023, GeneDx Holdings Corp. (the “Company”) issued a press release (the “Press Release”) and will hold a conference call announcing the Company's financial results for the three months ended March 31, 2023. Copies of the Press Release and Earnings Presentation are furnished as Exhibits 99.1 and 99.2, respectively, to this Current Report on Form 8-K.
The information furnished with this Item 2.02, including Exhibits 99.1 and 99.2 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
Exhibit No | Description | ||||
99.1 | |||||
99.2 | |||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| GeneDx Holdings Corp. | |||||||||||
| Date: | May 9, 2023 | By: | /s/ Katherine Stueland | ||||||||
| Name: | Katherine Stueland | ||||||||||
| Title: | Chief Executive Officer | ||||||||||
Exhibit 99.1
GeneDx Reports First Quarter 2023 Financial Results and Business Highlights
Generated $40.7 million in first quarter 2023 pro forma revenue from continuing operations, representing a 7% increase year over year
Revenue included $22.4 million in whole exome testing, representing a 22% increase year over year
Ongoing cost mitigation in first quarter delivered 31% cash burn improvement year-over-year
Company reaffirms pro forma full year 2023 guidance
GeneDx to host conference call today at 4:30 p.m. ET
STAMFORD, Conn., May 9, 2023 — GeneDx Holdings Corp. (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today reported its financial results for the first quarter of 2023.
“Our distinct strength in delivering genomic interpretation continues to play a growing role in the diagnosis of rare diseases, and we’re on our way to establishing a new standard of care. We served a record number of patients this quarter with strong and accelerating whole exome test growth, as well as other tests that play a critically important role in diagnosing children across a broad range of rare but collectively common conditions. As we continue to strengthen our commercial footprint and increase awareness about higher diagnostic yields available with our exome and genome tests, we are encouraged by increased adoption among non-genetic specialists who ordered their first GeneDx exome test in the first quarter,” said Katherine Stueland, President and Chief Executive Officer of GeneDx. “Our efforts are amplified by guidelines from physician groups and updated payer coverage policies in support of our intent to drive a shift towards whole exome and genome sequencing, ultimately driving better patient care while delivering revenue growth and margin expansion going forward.”
GeneDx Pro Forma First Quarter Financial Results from Continuing Operations1
Pro forma results from continuing operations for GeneDx reported today include the combination of Legacy GeneDx and only the data and information business of Legacy Sema4, and assume Legacy GeneDx was owned for the entirety of 2022. Continuing operations exclude revenues and costs from the now discontinued Legacy Sema4 diagnostics testing business.
•Revenue: Pro forma revenue from continuing operations for the first quarter of 2023 was $40.7 million, compared to $38.0 million in the first quarter of 2022, representing an increase of 7% year-over-year. Revenues from whole exome and genome tests were $22.4 million compared to $18.4 million in the first quarter of 2022, representing an increase of 22% year-over-year.
•Test Volume: Total tests resulted in the first quarter of 2023 were nearly 53,000, compared to over 41,000 for the first quarter of 2022. Total whole exome and whole genome tests resulted were approximately 8,700, an increase of 18% compared to the first quarter of 2022.
•Gross Margin: Pro forma adjusted gross margin from continuing operations in the first quarter of 2023 was 34%.
Total Company First Quarter Financial Results Including Now Discontinued Legacy Sema4 Diagnostic Testing Business1
Total Company results reported today for the first quarter of 2023 include the combination of continuing operations and the now discontinued Legacy Sema4 diagnostic testing business. All comparable 2022
information presented below excludes any Legacy GeneDx revenues and associated costs due to the timing of the acquisition of GeneDx which closed in the second quarter of 2022.
•Total Company Cash Position: Total cash and cash equivalents and restricted cash were $214.0 million as of March 31, 2023. Total Company burn for the first quarter of 2023 was $58.8 million, an improvement of 31% year-over-year.
•Net Loss1: Total Company net loss for the first quarter of 2023 was ($60.4) million. Total Company adjusted net loss for the first quarter of 2023 was ($48.9) million2 compared to adjusted net loss of ($62.4) million for the first quarter of 2022, an improvement of 23% year-over-year.
•Revenue1: Total Company revenue for the first quarter of 2023 was $43.1 million, compared to $53.9 million in the first quarter of 2022.
•Gross Margin1: Total Company gross margin for the first quarter of 2023 was 35%, with an adjusted gross margin of 33%2 in the quarter.
Recent Business Highlights
Financial & Corporate Growth
•Closed the underwritten public offering and concurrent registered direct offering for total gross proceeds of approximately $150 million
•Appointed Devin K. Schaffer, J.D., M.B.A., as General Counsel
Commercial Updates
•Presented or collaborated with researchers to showcase new data in 10 posters and presentations at the American College of Medical Genetics (ACMG) Annual Clinical Genetics Meeting
•Presented data demonstrating the diagnostic advantages of exome sequencing compared with chromosomal microarray (CMA)
•Exome sequencing had a copy number variant (CNV) detection rate of 93.4%, factoring in that some CMA-reported CNVs were detected by exome sequencing but not reported due to lack of phenotypic fit.
•Additionally, for CMA negative cases, exome sequencing found a CNV in 1.3% of these cases, mostly due to limitations in CMA probe coverage.
•Collaborated in the presentation of initial data and analysis from the GUARDIAN study presented at the ACMG Annual Clinical Genetics Meeting showing whole genome sequencing identified rare genetic conditions not otherwise part of standard newborn screening.
•Of the 1,000 newborns enrolled to date, true positive screening outcomes were present in 2.6% of newborns. This included 15 confirmed cases with G6PD deficiency, a genetic disorder not integrated with standard newborn screening.
•In a retrospective analysis performed by GeneDx, of almost 25,000 individuals with positive exome or genome sequencing, more than 20% of individuals could have identified their genetic disease on average, 7 to 11 years sooner had they received genome sequencing at birth.
•Initiated outreach to physicians highlighting recent policy updates from UnitedHealthcare® and Cigna® providing both whole exome sequencing and whole genome sequencing coverage under their commercial plans to diagnose complex diseases and guide personalized medical treatment plans
•Signed agreements with five biopharmaceutical companies focused on rare diseases or neurological disorders to deliver insightful and actionable information based on GeneDx dataset
•Launched buccal swab, or cheek swab, for whole genome sequencing of biological parents to aid in disease diagnosis
GeneDx Pro Forma Full Year 2023 Guidance
GeneDx is reiterating its previously issued full year 2023 guidance. The continuing operations of GeneDx, excluding revenues and direct costs from the now discontinued Legacy Sema4 diagnostic testing business, are expected to:
•Generate revenues between $205 to $220 million for full year 2023;
•Expand gross margin profile in 2023 and beyond;
•Use $95 to $110 million of net cash in 2023 for continuing operations. Inclusive of servicing obligations of the exited business activities, the Company’s cash burn in 2023 is expected to be in the range of $130 to $145 million; and
•Turn profitable in 2025.
1 The pro forma unadjusted and adjusted results from continuing operations for the first quarter of 2023 and the comparable results for for the first quarter of 2022 are presented on a pro forma basis assuming Legacy GeneDx and the Company were combined for the entirety of 2022 and exclude the revenues and costs from the now discontinued Legacy Sema4 diagnostic testing business, and include the combination of the Legacy GeneDx diagnostic business revenues and costs with the data and information revenues and associated costs derived from the Legacy Sema4 business. Actual total Company results include the results of the Legacy GeneDx business only from the date of the Company’s acquisition of Legacy GeneDx on April 29, 2022, the purchase accounting associated with the acquisition of Legacy GeneDx, and also include the financial impacts of exited Legacy Sema4 business activities for the full quarter.
2 Adjusted gross margin and adjusted net loss are non-GAAP financial measures. See appendix for a reconciliation of GAAP to Non-GAAP figures presented.
Webcast and Conference Call Details
GeneDx will host a conference call today, May 9, 2023, at 4:30 p.m. Eastern Time. Investors interested in listening to the conference call are required to register online. A live and archived webcast of the event will be available on the “Events” section of the GeneDx investor relations website at https://ir.genedx.com/.
Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of the federal securities laws, including statements regarding our future performance and our market opportunity, including our expected full year 2023 reported revenue guidance, our expectations regarding our gross margin profile in 2023 and beyond, our use of cash for continuing operations and our cash burn in 2023 and our turning profitable in 2025, our expectations for our growth and future investment in our business, our expectations regarding our plans to pursue new strategic direction, improve our operational efficiency and reduce our cash burn and our ability to scale to profitability, the associated cost savings of our business exits and impact on our gross margins. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: (i) our ability to implement business plans, goals and forecasts, and identify and realize additional opportunities, (ii) the risk of downturns and a changing regulatory landscape in the highly competitive healthcare industry, (iii) the size and growth of the market in which we operate, and (iv) our ability to pursue our new strategic direction. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of our Annual Report on Form 10-K for the fiscal year ended December 31, 2022, filed with the U.S. Securities and Exchange Commission (the “SEC”) on March 16, 2023, and other documents filed by us from time to time with the SEC. These filings identify
and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and we assume no obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. We do not give any assurance that we will achieve our expectations.
About GeneDx
GeneDx (Nasdaq: WGS) delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. GeneDx is at the forefront of transforming healthcare through its industry-leading exome and genome testing and interpretation, fueled by one of the world’s largest rare disease data sets. For more information, please visit genedx.com and connect with us on LinkedIn, Facebook, Twitter and Instagram.
Investor Relations Contact:
Tricia Truehart
Investors@GeneDx.com
Media Contact:
Maurissa Messier
Press@GeneDx.com
Pro forma select volume and revenue from Continuing Operations in the table below assumes Legacy GeneDx was owned for the entirety of the applicable quarter(s) and are calculated based on the construct of our continuing operations inclusive of Legacy GeneDx combined with data revenues and associated costs from Legacy Sema4. Pro forma select metrics are presented for illustrative purposes only and are not necessarily indicative of the results that would have occurred had the GeneDx acquisition been completed on such dates or that may occur in the future.
Pro Forma Select GeneDx Volume & Revenue from Continuing Operations
| 1Q22 | 2Q22 | 3Q22 | 4Q22 | 1Q23 | |||||||||||||
| Volumes | |||||||||||||||||
| Whole Exome, Whole Genome | 7,397 | 7,579 | 7,722 | 7,862 | 8,705 | ||||||||||||
| Exome based Panels | 2,630 | 3,141 | 2,983 | 3,013 | 3,136 | ||||||||||||
| Hereditary Cancer | 6,429 | 7,391 | 5,445 | 6,069 | 7,120 | ||||||||||||
| Other individual gene tests and multi-gene disease panels | 24,610 | 27,446 | 28,764 | 31,891 | 33,817 | ||||||||||||
| Total | 41,066 | 45,557 | 44,914 | 48,835 | 52,778 | ||||||||||||
| Revenue | |||||||||||||||||
| Whole Exome, Whole Genome | $18.4 | $21.1 | $24.0 | $23.3 | $22.4 | ||||||||||||
| Exome based Panels | $2.4 | $2.4 | $2.3 | $2.0 | $2.0 | ||||||||||||
| Hereditary Cancer | $2.8 | $3.8 | $3.5 | $4.4 | $4.3 | ||||||||||||
| Other individual gene tests and multi-gene disease panels | $12.8 | $10.5 | $15.6 | $14.3 | $10.6 | ||||||||||||
| Data Information | $1.6 | $2.3 | $1.8 | $1.9 | $1.3 | ||||||||||||
| Total | $38.0 | $40.1 | $47.2 | $45.8 | $40.7 | ||||||||||||
Unaudited Pro forma select financial information assume Legacy GeneDx was owned for the entirety of the quarter and is calculated based on the construct of our continuing operations inclusive of Legacy GeneDx combined with data revenues and associated costs from Legacy Sema4. Unaudited Pro forma select financial information is presented for illustrative purposes only and are not necessarily indicative of the results that would have occurred had the Legacy GeneDx acquisition been completed on such dates or that may occur in the future.
UNAUDITED PRO FORMA SELECT FINANCIAL INFORMATION
FOR THE THREE MONTHS ENDED MARCH 31, 2023
(in thousands)
| GeneDx Continuing Operations | Legacy Sema4 Discontinued Business | Combined Company | |||||||||
| Revenue | 40,693 | 2,446 | 43,139 | ||||||||
| Adjusted Cost of Services | 26,826 | 2,080 | 28,906 | ||||||||
| Adjusted Gross Margin | 13,867 | 366 | 14,233 | ||||||||
| Adjusted Gross Margin % | 34.1% | 14.9% | 33.0% | ||||||||
Total Company results below for the first quarter of 2023 include the combination of continuing operations and the now discontinued Legacy Sema4 diagnostic testing business.
GeneDx Holdings Corp.
Reconciliation of Revenue to Adjusted Gross Margin & Adjusted Operating Loss
(unaudited, in thousands)
| Three Months Ended March 31, | |||||
| 2023 | |||||
| Revenue | |||||
| Diagnostic test revenue | 41,850 | ||||
| Other Revenue | 1,289 | ||||
| Total Revenue | 43,139 | ||||
| Cost of Service | 27,903 | ||||
| Gross (Loss) Profit | 15,236 | ||||
| Gross Margin | 35.3% | ||||
| Depreciation and Amortization | 589 | ||||
| Stock-based compensation | (1,666) | ||||
| Restructuring costs | 74 | ||||
| Adjusted Gross (Loss) Profit | 14,233 | ||||
| Adjusted Gross Margin | 33% | ||||
| Research & Development | 14,592 | ||||
| Depreciation and Amortization | 852 | ||||
| Stock-based compensation | 943 | ||||
| Restructuring costs | 91 | ||||
| Adjusted Research & Development | 12,706 | ||||
| Selling & Marketing | 13,452 | ||||
| Depreciation and Amortization | 1,226 | ||||
| Stock-based compensation | 63 | ||||
| Restructuring costs | 142 | ||||
| Adjusted Selling & Marketing | 12,022 | ||||
| General & Administrative & Related Party Expense | 45,436 | ||||
| Depreciation and Amortization | 5,968 | ||||
| Stock-based compensation | 709 | ||||
| Restructuring costs | 395 | ||||
| Adjusted General & Administrative & Related Party | 38,364 | ||||
| Total Adjusted Operating Expenses | 63,092 | ||||
| Impairment Loss | 2,120 | ||||
| Loss from Operations | (60,364) | ||||
| Depreciation and Amortization | 8,636 | ||||
| Stock-based compensation | 48 | ||||
| Restructuring costs | 702 | ||||
| Impairment Loss | 2,120 | ||||
| Adjusted loss from operations | (48,858) | ||||
The financial statements that follow represents our preliminary unaudited consolidated financial statements for the quarter ended March 31, 2023 and year ended December 31, 2022, subject to change, which have been prepared in accordance with U.S. GAAP. Results include the combination of Legacy GeneDx and Legacy Sema4 with the activities of Legacy GeneDx only from the April 29, 2022 acquisition date.
GeneDx Holdings Corp.
Consolidated Balance Sheets
(in thousands, except share and per share amounts)
| March 31, 2023 (unaudited) | December 31, 2022 | ||||||||||
| Assets | |||||||||||
| Current assets: | |||||||||||
| Cash and cash equivalents | $ | 201,895 | $ | 123,933 | |||||||
| Restricted cash | 12,144 | 13,470 | |||||||||
| Accounts receivable, net | 32,911 | 42,634 | |||||||||
| Due from related parties | 636 | 708 | |||||||||
| Inventory, net | 12,334 | 13,665 | |||||||||
| Prepaid expenses and other current assets | 12,428 | 18,212 | |||||||||
| Total current assets | $ | 272,348 | $ | 212,622 | |||||||
| Operating lease right-of-use assets | 49,508 | 51,527 | |||||||||
| Property and equipment, net | 33,235 | 32,758 | |||||||||
| Intangible assets, net | 183,144 | 186,650 | |||||||||
| Long-term restricted cash | 900 | 900 | |||||||||
| Other assets | 6,160 | 6,485 | |||||||||
| Total assets | $ | 545,295 | $ | 490,942 | |||||||
Liabilities and Stockholders’ Equity | |||||||||||
| Current liabilities: | |||||||||||
| Accounts payable and accrued expenses | 69,889 | 84,878 | |||||||||
| Due to related parties | 4,315 | 3,593 | |||||||||
| Short-term lease liabilities | 5,199 | 6,121 | |||||||||
| Other current liabilities | 39,629 | 49,705 | |||||||||
| Total current liabilities | 119,032 | 144,297 | |||||||||
| Long-term debt, net of current portion | 6,250 | 6,250 | |||||||||
| Long-term lease liabilities | 63,883 | 60,013 | |||||||||
| Other liabilities | 2,510 | 2,659 | |||||||||
| Deferred taxes | 22,111 | 22,000 | |||||||||
| Warrant liability | 440 | 418 | |||||||||
| Earn-out contingent liability | 2,600 | 1,600 | |||||||||
| Total liabilities | $ | 216,826 | $ | 237,237 | |||||||
| Commitments and contingencies | |||||||||||
| Stockholders’ Equity: | |||||||||||
Preferred Stock, $0.0001 par value: 1,000,000 and 1,000,000 shares authorized at March 31, 2023 and December 31, 2022, respectively; 0 shares issued and outstanding at March 31, 2023 and December 31, 2022, respectively | — | — | |||||||||
Class A common stock, $0.0001 par value: 1,000,000,000 and 1,000,000,000 shares authorized at March 31, 2023 and December 31, 2022, respectively, 24,193,436 and 11,773,065 shares issued and outstanding at March 31, 2023 and December 31, 2022, respectively | 2 | 1 | |||||||||
| Additional paid-in capital | 1,513,877 | 1,378,125 | |||||||||
| Accumulated deficit | (1,185,410) | (1,124,421) | |||||||||
| Total stockholders’ equity | $ | 328,469 | $ | 253,705 | |||||||
Total liabilities and stockholders’ equity | $ | 545,295 | $ | 490,942 | |||||||
GeneDx Holdings Corp.
Consolidated Statements of Operations and Comprehensive Loss
(in thousands, except per share and share amounts)
| Three months ended March 31, | |||||||||||
| 2023 | 2022 | ||||||||||
| Revenue | |||||||||||
| Diagnostic test revenue | $ | 41,850 | $ | 52,495 | |||||||
| Other revenue | 1,289 | 1,446 | |||||||||
| Total revenue | 43,139 | 53,941 | |||||||||
Cost of services | 27,903 | 48,316 | |||||||||
| Gross profit | 15,236 | 5,625 | |||||||||
| Research and development | 14,592 | 21,315 | |||||||||
| Selling and marketing | 13,452 | 25,629 | |||||||||
| General and administrative | 43,689 | 46,702 | |||||||||
| Related party expenses | 1,747 | 1,284 | |||||||||
| Impairment loss | 2,120 | — | |||||||||
| Loss from operations | (60,364) | (89,305) | |||||||||
| Other income (expense): | |||||||||||
| Change in fair market value of warrant and earn-out contingent liabilities | (3,453) | 13,190 | |||||||||
| Interest income | 732 | 27 | |||||||||
| Interest expense | (767) | (808) | |||||||||
| Other income, net | 2,716 | — | |||||||||
| Total other (expense) income, net | (772) | 12,409 | |||||||||
| Loss before income taxes | (61,136) | (76,896) | |||||||||
| Income tax benefit | 147 | — | |||||||||
| Net loss and comprehensive loss | $ | (60,989) | $ | (76,896) | |||||||
| Weighted average shares outstanding of Class A common stock | 20,061,945 | 7,405,114 | |||||||||
| Basic and diluted net loss per share, Class A common stock | $ | (3.04) | $ | (10.38) | |||||||
GeneDx Holdings Corp.
Consolidated Statements of Cash Flows
(in thousands)
| Three months ended March 31, | |||||||||||
| 2023 | 2022 | ||||||||||
| Operating activities | |||||||||||
| Net loss | $ | (60,989) | $ | (76,896) | |||||||
Adjustments to reconcile net loss to net cash used in operating activities: | |||||||||||
| Depreciation and amortization expense | 8,636 | 5,803 | |||||||||
| Impairment loss | 2,120 | — | |||||||||
| Gain on debt forgiveness | (2,750) | — | |||||||||
| Stock-based compensation expense | 48 | 17,559 | |||||||||
| Change in fair value of warrant and contingent liabilities | 3,453 | (13,190) | |||||||||
| Provision for excess and obsolete inventory | — | 43 | |||||||||
| Non-cash lease expense | 146 | 167 | |||||||||
| Deferred tax benefit | (147) | — | |||||||||
| Amortization of debt issuance costs | 128 | 128 | |||||||||
| Change in operating assets and liabilities: | |||||||||||
| Accounts receivable | 9,723 | (11,132) | |||||||||
| Inventory | 1,331 | (2,904) | |||||||||
| Prepaid expenses and other current assets | 4,232 | 1,596 | |||||||||
| Due to/from related parties | 793 | 543 | |||||||||
| Other assets | (55) | (151) | |||||||||
| Accounts payable and accrued expenses | (14,470) | 3,932 | |||||||||
| Contract liabilities | — | (408) | |||||||||
| Other current liabilities | (7,759) | (6,584) | |||||||||
| Net cash used in operating activities | (55,560) | (81,494) | |||||||||
| Investing activities | |||||||||||
| Purchases of property and equipment | — | (1,378) | |||||||||
| Development of internal-use software assets | (462) | (2,535) | |||||||||
| Net cash used in investing activities | (462) | (3,913) | |||||||||
| Financing activities | |||||||||||
| Proceeds from underwritten public offering, net of issuance costs | 135,439 | — | |||||||||
| Long-term debt principal payment | (2,000) | — | |||||||||
| Finance lease payoff | (438) | — | |||||||||
| Finance lease principal payments | (609) | (862) | |||||||||
| Exercise of stock options | 266 | 702 | |||||||||
| Net cash provided by financing activities | 132,658 | (160) | |||||||||
Net (decrease) increase in cash, cash equivalents and restricted cash | 76,636 | (85,567) | |||||||||
| Cash, cash equivalents and restricted cash, at beginning of year | 138,303 | 401,469 | |||||||||
| Cash, cash equivalents and restricted cash, at end of year | $ | 214,939 | $ | 315,902 | |||||||
May 9, 2023 One Test: Miss Less. Discover More. GeneDx (Nasdaq: WGS) 1Q 2023 Earnings Presentation
2 Disclaimer This presentation contains forward-looking statements under the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that do not relate to historical facts and events and such statements and opinions pertaining to the future that, for example, contain wording such as “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “objective,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue,” “ongoing,” or the negative of these terms, or other comparable terminology intended to identify statements about the future. Forward-looking statements contained in this presentation may include, but are not limited to, statements about: our future performance and our market opportunity, our expected full year 2023 reported revenue guidance, our expectations regarding our gross margin profile in 2023 and beyond, our use of cash for continuing operations and our cash burn in 2023 and our turning profitable in 2025, our expectations for our growth and future investment in our business, our expectations regarding our plans to pursue a new strategic direction, improve our operational efficiency and reduce our cash burn and our ability to scale to profitability, the associated cost savings of our business exits and impact on our gross margins.. We cannot assure that the forward-looking statements in this presentation will prove to be accurate. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. The forward-looking statements and opinions contained in this presentation are based on our management’s beliefs and assumptions and are based upon information currently available to our management as of the date of this presentation and, while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. Many factors could cause actual future events to differ materially from the forward-looking statements in this presentation, including but not limited to: (i) the ability to implement business plans, goals and forecasts, and identify and realize additional opportunities, (ii) the risk of downturns and a changing regulatory landscape in the highly competitive healthcare industry, (iii) the size and growth of the market in which we operate, and (iv) our ability to pursue our new strategic direction. The information, opinions and forward- looking statements contained in this announcement speak only as of its date and are subject to change without notice. Use of Non-GAAP Financial Measures This presentation includes non-GAAP financial measures, including Adjusted Gross Profit (Loss), Adjusted Gross Margin and Adjusted EBITDA. We define Adjusted Gross Profit (Loss) as revenue less cost of services, excluding stock-based compensation expense and restructuring costs, and we define Adjusted Gross Margin as our Adjusted Gross Profit (Loss) divided by our revenue. We define Adjusted EBITDA as our net loss adjusted for interest expense, net, income tax expense, depreciation and amortization, stock-based compensation expense, transaction, acquisition and business integration costs, restructuring costs, change in fair market value of financial liabilities and other income. Management believes that these non-GAAP measures of financial results are useful in evaluating the GeneDx's operating performance compared to that of other companies in its industry, as these metrics generally eliminate the effects of certain items that may vary from company to company for reasons unrelated to overall operating performance. Please refer to our earnings release for a reconciliation of GAAP to non-GAAP financial measures. This presentation contains estimates, projections and other information concerning our industry, our business, and the markets for our products and services. Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties, and actual events or circumstances may differ materially from events and circumstances that are assumed in this information. Unless otherwise expressly stated, we obtained this industry, business, market and other data from our own internal estimates and research as well as from reports, research surveys, studies and similar data prepared by market research firms and other third parties, industry, medical and general publications, government data and similar sources. While we believe our internal company research as to such matters is reliable and the market definitions are appropriate, neither such research nor these definitions have been verified by any independent source. We discuss these and other risks and uncertainties in greater detail in the sections entitled “Risk Factors” and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in our periodic reports and other filings we make with the SEC from time to time. Given these uncertainties, you should not place undue reliance on the forward-looking statements. Moreover, we operate in a very competitive and rapidly changing environment. New risks emerge from time to time. Except as required by law, we undertake no obligation to update publicly any forward-looking statements for any reason after the date of this presentation to conform these statements to actual results or to changes in our expectations. We file reports, proxy statements, and other information with the SEC. Such reports, proxy statements, and other information concerning us are available www.sec.gov. Requests for copies of such documents should be directed to our Investor Relations department at GeneDx Holdings Corp. 333 Ludlow Street, North Tower, Stamford, Connecticut, 06902. Our telephone number is 800-298-6470.
Our mission: deliver personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery.
1Q 2023 and Recent Highlights 4 Generated $40.7 million in first quarter 2023 pro forma revenue from continuing operations, representing a 7% increase year over year $214.1M in cash, cash equivalents and restricted cash as of 3/31/23; fully funded to expected profitability in 2025 Reaffirms pro forma full year 2023 guidance Ongoing cost mitigation efforts delivering 31% reduction in cash burn year-over-year Revenue included $22.4 million in whole exome testing, representing a 22% increase year over year
Strong Momentum Across Pro Forma Volume & Revenue from Continuing Operations 5 Q1 2023 Volume Mix Q1 2023 Revenue Mix1 ~53k tests Q1 total volume +29% YoY1 8,705 Q1 Whole Exome / Whole Genome tests +18% YoY $39.4M Q1 total revenue from testing +8% YoY1 34% adj gross margin $171.0M 2022 total revenue 39% adj gross margin 1 The pro forma unadjusted and adjusted results from continuing operations for 2023 including the comparable results for 2022, are presented on a pro forma basis assuming Legacy GeneDx and the Company were combined for the entirety of 2022 and exclude the revenues and costs from the now discontinued Legacy Sema4 diagnostic testing business, and include the combination of the Legacy GeneDx diagnostic business revenues and costs with the data and information revenues and associated costs derived from the Legacy Sema4 business. Actual total Company results include the results of the Legacy GeneDx business only from the date of the Company’s acquisition of Legacy GeneDx on April 29, 2022, the purchase accounting associated with the acquisition of Legacy GeneDx, and also include the financial impacts of exited Legacy Sema4 business activities for the full year. WES/WGS 17% Exome Based 6% Hereditary Cancer 13%Other Tests 64% WES/WGS 57% Exome Based 5% Hereditary Cancer 11% Other Tests 27%
v Revenues between $205-220 million for full year 2023 Expanded adjusted gross margin profile 2023 and beyond Inclusive of servicing obligations of the exited business activities, total cash burn in 2023 between $130-145 million, a >50% reduction year-over-year Use of net $95-110 million in cash in 2023 for continuing operations Turn to profitability in 2025 2023 Guidance